GlaxoSmithKline and Sanofi have joined forces in the development of a vaccine against COVID-19

Pharmaceutical companies GlaxoSmithKline and Sanofi entered into an agreement on joint development of a vaccine for the prevention COVID-19, according to PharmaTimes. Under the agreement, Sanofi will provide to surface antigen s-protein of coronaviruses, and GlaxoSmithKline – your experience in the development of adjuvants.

In the development of new vaccines will involve recombinant DNA technology, already tested in the production of flu vaccines. Add company GlaxoSmithKline adjuvant will enhance the immune response to the vaccine.

Earlier, Sanofi announced that studies of recombinant vaccine COVID-19 carried out with the support of the office of advanced biomedical research and development USA (BARDA).

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]